Our model
The journey from target identification to developing a new drug treatment can be long and challenging without the collaboration and combined expertise of skilled professionals. At Axxam, we work closely with our clients’ scientists to form a unified team, sharing our extensive expertise in assay development, hit identification, and hit-to-lead activities.
DiscoveryMAXX - start right, progress faster
Axxam offers the possibility to run discovery programs all the way to compounds with a profile suitable for the in vivo proof-of-concept in relevant animal models. The DiscoveryMAXX package is a comprehensive program that seamlessly continues from assay development through high-throughput screening (HTS) and hit qualification to hit-to-lead optimization. Hit compounds can be optimized towards an agreed target product profile by combining expert medicinal chemistry with our in vitro biology and pharmacology platforms, as well as other required capabilities in-sourced from trusted partners, for individual project needs, such as in vivo DMPK. Depending on the target of interest and available data on either target or ligand structure(s), the process will also be supported by computational chemistry.
DiscoveryMAXX provides clients with the opportunity to have a single partner driving and coordinating their discovery project from target selection to the generation of a small molecule lead candidate for in vivo testing. Thus DiscoveryMAXX completes our ambition to translate innovative biology into quality chemistry.
Our partners
To enhance our service offering, we collaborate with trusted partners, covering numerous steps required to advance hit identification projects initiated at Axxam through the drug discovery and part of the development process. By establishing a consortium of centers of excellence with specialized drug discovery platforms, we provide best-in-class, fully integrated drug discovery services that can seamlessly integrate with clients’ preferred providers.
While immortalized cell lines might be the choice of election for High-Throughput Screening increasing the chance of finding good hits testing hundreds of thousands of molecules in a time and cost effective manner, using a more relevant and physiological environment such as primary cells or induced Pluripotent Stem Cells (iPSCs) offers a deep understanding of the biological mechanisms under investigation. Our preferred source of iPSCs is FUJIFILM Cellular Dynamics, Inc. (FCDI), with whom we have a long-standing collaboration.
When it comes to rodent primary cells and disease models, we rely on NeuroZone, an Italian company located in our campus that guarantees the access to fresh material
Symeres, a leading European contract research organization, is our preferred partners to work with to support the Hit-to-Lead journey of our clients. They offer innovative solutions to medicinal chemistry, synthetic chemistry, ADME-tox, integrated drug discovery, route-scouting and process research, GMP production. Thanks to our strategic alliance with Symeres, we offer our client also the possibility to screen the Symegold collection of approximatively 75.000 lead-like compounds synthesized at Symeres covering a lead-like diversity space not available in existing commercial libraries.
Through our relationship with Zobio, we offer biophysics and structural biology services to our clients, including protein engineering and production, fragment screening, structural biology with the combination of NMR spectroscopy and X-ray crystallography, biocore assays/screens, SPR assays.
Through LeadXPro, our clients have access to integral membrane protein structure and biophysics capabilities, such as protein design and generation, X-ray crystallography, cryo-electron microscopy, binding studies, Creoptix biophysical assays.
